How body composition and inflammation affect outcomes in bladder cancer
Official title: Impact of Body Composition and Related Inflammatory and Immune States on Prognosis of Non-Muscle Invasive Bladder Cancer
Funded at Kaiser Foundation Research Institute · NIH-11096087 · Data updated 2026-11-12
This study is looking at how things like weight and muscle loss affect the health and treatment of people with early-stage bladder cancer, hoping to find ways to better predict outcomes and tailor treatments for patients.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Kaiser Foundation Research Institute NIH-funded |
| Lab location | 1 site (Oakland, UNITED STATES) |
| Project start | June 14, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $874,216 |
| NIH project number | 5U01CA280991-03 |
| Project ID | NIH-11096087 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are newly diagnosed patients with non-muscle-invasive bladder cancer, particularly those who may be experiencing obesity or age-related muscle loss.
✕Less likely to help
Patients with muscle-invasive bladder cancer or those who do not have any body composition concerns may not benefit from this research.
What this research studies
This research investigates the relationship between body composition, inflammation, and immune responses in patients with non-muscle-invasive bladder cancer (NMIBC). It aims to understand how factors such as obesity and age-related muscle loss influence cancer prognosis and treatment response. By analyzing data from a large cohort of newly diagnosed NMIBC patients, the study will explore how these body composition characteristics may impact patient outcomes. The findings could lead to improved prognostic tools and personalized treatment strategies for bladder cancer patients.
Why it matters
Potential benefit: If successful, this research could lead to better prognostic assessments and tailored treatment options for bladder cancer patients based on their body composition and inflammatory status.
How similar studies have gone: Previous research has shown that body composition and inflammatory states can significantly influence cancer outcomes, suggesting that this approach may yield valuable insights.
Where this research is happening
-
Kaiser Foundation Research Institute
Oakland, United States Active
Researchers
- Principal investigator: Kwan, Marilyn L — Kaiser Foundation Research Institute
- Study coordinator: Kwan, Marilyn L
Related research
Other NIH-funded projects on the same topics.
-
Body fats and immune signals shaping bladder cancer outlook
This study will look at how body composition and immune/inflammatory states at diagnosis relate to the outlook for people with non-muscle-invasive bladder cancer.
-
Nrf2 in T cells and how it could boost immune power against bladder cancer
A small grant will explore how a T-cell protein called Nrf2 affects muscle-invasive bladder cancer and whether targeting it could help patients respond better to immune therapies.
-
Repurposing spironolactone to treat bladder cancer inside the bladder
Aims to repurpose spironolactone as an intravesical treatment for non-muscle invasive bladder cancer to help prevent recurrence and progression.
-
Novel combination immunotherapy for non–muscle-invasive bladder cancer
Researchers are testing a new combination approach using a special anti-CD40 antibody with existing bladder cancer therapies to help patients whose NMIBC did not respond to standard BCG treatment.
-
Why some bladder cancers don't respond to BCG treatment
This project will use detailed tissue and genetic tests to look for what makes some non-muscle invasive bladder cancers resist BCG so better treatments can be found for people who don't respond.
-
Salt-based nanomedicine to treat bladder cancer that doesn’t respond to standard BCG therapy
A patient-focused overview of a new salt-based nanoparticle therapy designed to target non-muscle invasive bladder cancer that is resistant to BCG treatment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.